JoAnn E Manson1, Aaron K Aragaki2, Shari S Bassuk1, Rowan T Chlebowski3, Garnet L Anderson2, Jacques E Rossouw4, Barbara V Howard5, Cynthia A Thomson6, Marcia L Stefanick7, Andrew M Kaunitz8, Carolyn J Crandall9, Charles B Eaton10, Victor W Henderson11, Simin Liu10, Juhua Luo12, Thomas Rohan13, Aladdin H Shadyab14, Gretchen Wells15, Jean Wactawski-Wende16, Ross L Prentice2. 1. Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (J.E.M., S.S.B.). 2. Fred Hutchinson Cancer Research Center, Seattle, Washington (A.K.A., G.L.A., R.L.P.). 3. City of Hope National Medical Center, Duarte, and Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California (R.T.C.). 4. National Heart, Lung, and Blood Institute, Bethesda, Maryland (J.E.R.). 5. MedStar Health Research Institute, Bonita Springs, Florida, and Georgetown-Howard Universities, Washington, DC (B.V.H.). 6. Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona (C.A.T.). 7. Stanford Prevention Research Center, Stanford, California (M.L.S.). 8. University of Florida College of Medicine-Jacksonville, Jacksonville, Florida (A.M.K.). 9. David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California (C.J.C.). 10. Alpert Medical School of Brown University, Providence, Rhode Island (C.B.E., S.L.). 11. Stanford University, Stanford, California (V.W.H.). 12. Brown University, Providence, Rhode Island; Indiana University, Bloomington, Indiana (J.L.). 13. Albert Einstein College of Medicine, Bronx, New York (T.R.). 14. University of California, San Diego School of Medicine, La Jolla, California (A.H.S.). 15. University of Kentucky, Lexington, Kentucky (G.W.). 16. University at Buffalo, the State University of New York, Buffalo, New York (J.W.).
Abstract
Background: Whether health outcomes of menopausal estrogen therapy differ between women with and without bilateral salpingo-oophorectomy (BSO) is unknown. Objective: To examine estrogen therapy outcomes by BSO status, with additional stratification by 10-year age groups. Design: Subgroup analyses of the randomized Women's Health Initiative Estrogen-Alone Trial. (ClinicalTrials.gov: NCT00000611). Setting: 40 U.S. clinical centers. Participants: 9939 women aged 50 to 79 years with prior hysterectomy and known oophorectomy status. Intervention: Conjugated equine estrogens (CEE) (0.625 mg/d) or placebo for a median of 7.2 years. Measurements: Incidence of coronary heart disease and invasive breast cancer (the trial's 2 primary end points), all-cause mortality, and a "global index" (these end points plus stroke, pulmonary embolism, colorectal cancer, and hip fracture) during the intervention phase and 18-year cumulative follow-up. Results: The effects of CEE alone did not differ significantly according to BSO status. However, age modified the effect of CEE in women with prior BSO. During the intervention phase, CEE was significantly associated with a net adverse effect (hazard ratio for global index, 1.42 [95% CI, 1.09 to 1.86]) in older women (aged ≥70 years), but the global index was not elevated in younger women (P trend by age = 0.016). During cumulative follow-up, women aged 50 to 59 years with BSO had a treatment-associated reduction in all-cause mortality (hazard ratio, 0.68 [CI, 0.48 to 0.96]), whereas older women with BSO had no reduction (P trend by age = 0.034). There was no significant association between CEE and outcomes among women with conserved ovaries, regardless of age. Limitations: The timing of CEE in relation to BSO varied; several comparisons were made without adjustment for multiple testing. Conclusion: The effects of CEE did not differ by BSO status in the overall cohort, but some findings varied by age. Among women with prior BSO, in those aged 70 years or older, CEE led to adverse effects during the treatment period, whereas women randomly assigned to CEE before age 60 seemed to derive mortality benefit over the long term. Primary Funding Source: The WHI program is funded by the National Heart, Lung, and Blood Institute; National Institutes of Health; and U.S. Department of Health and Human Services. Wyeth Ayerst donated the study drugs.
RCT Entities:
Background: Whether health outcomes of menopausal estrogen therapy differ between women with and without bilateral salpingo-oophorectomy (BSO) is unknown. Objective: To examine estrogen therapy outcomes by BSO status, with additional stratification by 10-year age groups. Design: Subgroup analyses of the randomized Women's Health Initiative Estrogen-Alone Trial. (ClinicalTrials.gov: NCT00000611). Setting: 40 U.S. clinical centers. Participants: 9939 women aged 50 to 79 years with prior hysterectomy and known oophorectomy status. Intervention: Conjugated equine estrogens (CEE) (0.625 mg/d) or placebo for a median of 7.2 years. Measurements: Incidence of coronary heart disease and invasive breast cancer (the trial's 2 primary end points), all-cause mortality, and a "global index" (these end points plus stroke, pulmonary embolism, colorectal cancer, and hip fracture) during the intervention phase and 18-year cumulative follow-up. Results: The effects of CEE alone did not differ significantly according to BSO status. However, age modified the effect of CEE in women with prior BSO. During the intervention phase, CEE was significantly associated with a net adverse effect (hazard ratio for global index, 1.42 [95% CI, 1.09 to 1.86]) in older women (aged ≥70 years), but the global index was not elevated in younger women (P trend by age = 0.016). During cumulative follow-up, women aged 50 to 59 years with BSO had a treatment-associated reduction in all-cause mortality (hazard ratio, 0.68 [CI, 0.48 to 0.96]), whereas older women with BSO had no reduction (P trend by age = 0.034). There was no significant association between CEE and outcomes among women with conserved ovaries, regardless of age. Limitations: The timing of CEE in relation to BSO varied; several comparisons were made without adjustment for multiple testing. Conclusion: The effects of CEE did not differ by BSO status in the overall cohort, but some findings varied by age. Among women with prior BSO, in those aged 70 years or older, CEE led to adverse effects during the treatment period, whereas women randomly assigned to CEE before age 60 seemed to derive mortality benefit over the long term. Primary Funding Source: The WHI program is funded by the National Heart, Lung, and Blood Institute; National Institutes of Health; and U.S. Department of Health and Human Services. Wyeth Ayerst donated the study drugs.
Authors: Garnet L Anderson; Marian Limacher; Annlouise R Assaf; Tamsen Bassford; Shirley A A Beresford; Henry Black; Denise Bonds; Robert Brunner; Robert Brzyski; Bette Caan; Rowan Chlebowski; David Curb; Margery Gass; Jennifer Hays; Gerardo Heiss; Susan Hendrix; Barbara V Howard; Judith Hsia; Allan Hubbell; Rebecca Jackson; Karen C Johnson; Howard Judd; Jane Morley Kotchen; Lewis Kuller; Andrea Z LaCroix; Dorothy Lane; Robert D Langer; Norman Lasser; Cora E Lewis; JoAnn Manson; Karen Margolis; Judith Ockene; Mary Jo O'Sullivan; Lawrence Phillips; Ross L Prentice; Cheryl Ritenbaugh; John Robbins; Jacques E Rossouw; Gloria Sarto; Marcia L Stefanick; Linda Van Horn; Jean Wactawski-Wende; Robert Wallace; Sylvia Wassertheil-Smoller Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: William H Parker; Michael S Broder; Eunice Chang; Diane Feskanich; Cindy Farquhar; Zhimae Liu; Donna Shoupe; Jonathan S Berek; Susan Hankinson; JoAnn E Manson Journal: Obstet Gynecol Date: 2009-05 Impact factor: 7.661
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: JoAnn E Manson; Aaron K Aragaki; Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Rowan T Chlebowski; Barbara V Howard; Cynthia A Thomson; Karen L Margolis; Cora E Lewis; Marcia L Stefanick; Rebecca D Jackson; Karen C Johnson; Lisa W Martin; Sally A Shumaker; Mark A Espeland; Jean Wactawski-Wende Journal: JAMA Date: 2017-09-12 Impact factor: 56.272
Authors: Gerardo Heiss; Robert Wallace; Garnet L Anderson; Aaron Aragaki; Shirley A A Beresford; Robert Brzyski; Rowan T Chlebowski; Margery Gass; Andrea LaCroix; JoAnn E Manson; Ross L Prentice; Jacques Rossouw; Marcia L Stefanick Journal: JAMA Date: 2008-03-05 Impact factor: 56.272
Authors: JoAnn E Manson; Rowan T Chlebowski; Marcia L Stefanick; Aaron K Aragaki; Jacques E Rossouw; Ross L Prentice; Garnet Anderson; Barbara V Howard; Cynthia A Thomson; Andrea Z LaCroix; Jean Wactawski-Wende; Rebecca D Jackson; Marian Limacher; Karen L Margolis; Sylvia Wassertheil-Smoller; Shirley A Beresford; Jane A Cauley; Charles B Eaton; Margery Gass; Judith Hsia; Karen C Johnson; Charles Kooperberg; Lewis H Kuller; Cora E Lewis; Simin Liu; Lisa W Martin; Judith K Ockene; Mary Jo O'Sullivan; Lynda H Powell; Michael S Simon; Linda Van Horn; Mara Z Vitolins; Robert B Wallace Journal: JAMA Date: 2013-10-02 Impact factor: 56.272
Authors: Rowan T Chlebowski; Garnet L Anderson; Aaron K Aragaki; JoAnn E Manson; Marcia L Stefanick; Kathy Pan; Wendy Barrington; Lewis H Kuller; Michael S Simon; Dorothy Lane; Karen C Johnson; Thomas E Rohan; Margery L S Gass; Jane A Cauley; Electra D Paskett; Maryam Sattari; Ross L Prentice Journal: JAMA Date: 2020-07-28 Impact factor: 56.272
Authors: Anna C O'Kelly; Erin D Michos; Chrisandra L Shufelt; Jane V Vermunt; Margo B Minissian; Odayme Quesada; Graeme N Smith; Janet W Rich-Edwards; Vesna D Garovic; Samar R El Khoudary; Michael C Honigberg Journal: Circ Res Date: 2022-02-17 Impact factor: 17.367
Authors: Jaqueline S da Silva; Tadeu L Montagnoli; Bruna S Rocha; Matheus L C A Tacco; Sophia C P Marinho; Gisele Zapata-Sudo Journal: Int J Mol Sci Date: 2021-01-07 Impact factor: 5.923
Authors: Mengjie Zhang; Sarah Flury; Chun K Kim; Wilson C J Chung; Jonathan A Kirk; Toni R Pak Journal: Endocrinology Date: 2021-09-01 Impact factor: 5.051